Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRT1419 · 2 trials · 11 indications
Dose limiting toxicities will be evaluated through the first cycle
The MTD and/or OBD will be established for further investigation in participants with advanced solid tumors.
The RP2D will be established for further investigation in participants with advanced solid tumors.
Dose limiting toxicities will be evaluated through the first cycle
The MTD and/or OBD will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome
The RP2D will be established for further investigation in participants with multiple myeloma, Non-Hodgkin's Lymphoma, acute myeloid leukemia and myelodysplastic syndrome
| Arm | Type | Description |
|---|---|---|
| PRT1419 | EXPERIMENTAL | PRT1419 will be administered by intravenous infusion |
| Name | Type | Description |
|---|---|---|
| PRT1419 | DRUG | PRT1419 will be administered by intravenous infusion |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Adequate organ function (bone marrow, hepatic, renal, cardiovascular) * Left ventricular ejection fraction of ≥ 50% * Female patients of childbearing potential must have a negative pregnancy test within 7 da...
Top 20 of 25 competitors
PRT1419 is an investigational small molecule being studied for the treatment of relapsed or refractory hematologic malignancies, including multiple myeloma, acute myeloid leukemia, non-Hodgkin lymphoma, and myelodysplastic syndromes, as well as advanced solid tumors such as sarcoma, melanoma, lung cancer, breast cancer, esophageal cancer, cervical cancer, and head and neck cancer.
PRT1419 is being developed by Prelude Therapeutics Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol PRLD.
PRT1419 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 studies have been completed, one in hematologic malignancies and one in advanced solid tumors.
PRT1419 has been studied in two completed Phase 1 clinical trials. NCT04543305 evaluated PRT1419 in patients with relapsed or refractory hematologic malignancies, enrolling 16 participants. NCT04837677 evaluated PRT1419 in patients with advanced solid tumors, enrolling 26 participants. Both trials were conducted in the United States.
PRT1419 is a distinct investigational compound and is not known to be the same as any other approved or marketed drug. It is being developed by Prelude Therapeutics under its own unique identifier.